Since the above two studies were limited to cell lines, more in-depth investigation in patient specimens, primary cell lines, and animal experiments is required to determine the expression of RGC32 in gliomas and its mechanism in tumorigenesis and disease development. The gene discussed is RGCC; the disease is central nervous system cancer.